| Blood-based biomarkers for Alzheimer's disease: towards clinical implementation CE Teunissen, IMW Verberk, EH Thijssen, L Vermunt, O Hansson, ... The Lancet Neurology 21 (1), 66-77, 2022 | 520 | 2022 |
| Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype L Vermunt, SAM Sikkes, A Van Den Hout, R Handels, I Bos, ... Alzheimer's & Dementia 15 (7), 888-898, 2019 | 443 | 2019 |
| Severe early life stress hampers spatial learning and neurogenesis, but improves hippocampal synaptic plasticity and emotional learning under high-stress conditions in adulthood CA Oomen, H Soeters, N Audureau, L Vermunt, FN Van Hasselt, ... Journal of Neuroscience 30 (19), 6635-6645, 2010 | 399 | 2010 |
| Early maternal deprivation affects dentate gyrus structure and emotional learning in adult female rats CA Oomen, H Soeters, N Audureau, L Vermunt, FN Van Hasselt, ... Psychopharmacology 214, 249-260, 2011 | 158 | 2011 |
| The Alzheimer’s disease drug development landscape P Van Bokhoven, A de Wilde, L Vermunt, PS Leferink, S Heetveld, ... Alzheimer's Research & Therapy 13 (1), 186, 2021 | 72 | 2021 |
| Transitions across cognitive states and death among older adults in relation to education: a multistate survival model using data from six longitudinal studies A Robitaille, A Van Den Hout, RJM Machado, DA Bennett, I Čukić, ... Alzheimer's & dementia 14 (4), 462-472, 2018 | 70 | 2018 |
| Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort S Ingala, C De Boer, LA Masselink, I Vergari, L Lorenzini, K Blennow, ... Alzheimer's & Dementia 17 (7), 1189-1204, 2021 | 53 | 2021 |
| Detection and localization of early-and late-stage cancers using platelet RNA S GJG, M Arkani, E Post, M Antunes-Ferreira, S D’Ambrosi, DCL Vessies, ... Cancer Cell 40 (9), 999-1009. e6, 2022 | 41 | 2022 |
| Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease E Dicks, L Vermunt, WM van der Flier, PJ Visser, F Barkhof, P Scheltens, ... NeuroImage: Clinical 22, 101786, 2019 | 38 | 2019 |
| CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels M Del Campo, CFW Peeters, ECB Johnson, L Vermunt, YS Hok-A-Hin, ... Nature aging 2 (11), 1040-1053, 2022 | 36 | 2022 |
| Age‐and disease‐specific reference values for neurofilament light presented in an online interactive support interface L Vermunt, M Otte, IMW Verberk, J Killestein, AW Lemstra, ... Annals of Clinical and Translational Neurology 9 (11), 1832-1837, 2022 | 36 | 2022 |
| Dutch Brain Research Registry for study participant recruitment: design and first results MD Zwan, WM van der Flier, S Cleutjens, TC Schouten, L Vermunt, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 7 (1 …, 2021 | 36 | 2021 |
| Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview C Delaby, CE Teunissen, K Blennow, D Alcolea, I Arisi, EB Amar, ... Alzheimer's & Dementia 18 (10), 1868-1879, 2022 | 35 | 2022 |
| Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals BM Tijms, L Vermunt, MD Zwan, AC van Harten, WM van der Flier, ... Annals of Clinical and Translational Neurology 5 (9), 1037-1047, 2018 | 31 | 2018 |
| Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles BM Tijms, EM Vromen, O Mjaavatten, H Holstege, LM Reus, ... Nature aging 4 (1), 33-47, 2024 | 30 | 2024 |
| The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: implications for trial design D Bertens, BM Tijms, L Vermunt, ND Prins, P Scheltens, PJ Visser, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 3 (4 …, 2017 | 26 | 2017 |
| European Prevention of Alzheimer's Dementia Registry: recruitment and prescreening approach for a longitudinal cohort and prevention trials L Vermunt, CD Veal, L Ter Meulen, C Chrysostomou, W van der Flier, ... Alzheimer's & Dementia 14 (6), 837-842, 2018 | 23 | 2018 |
| Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition P Chatterjee, L Vermunt, B Gordon, S Pedrini, L Boonkamp, N Armstrong, ... Alzheimer's & Dementia, 2022, 2022 | 22* | 2022 |
| CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease EL Van Der Ende, SGJG In ‘t Veld, I Hanskamp, S Van Der Lee, ... Brain 146 (11), 4495-4507, 2023 | 17 | 2023 |
| Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal L Vermunt, AJL van Paasen, CE Teunissen, P Scheltens, PJ Visser, ... Neurology 92 (23), e2699-e2705, 2019 | 17 | 2019 |
